New York, USA and Adelaide, Australia – 25th July 2025
GPN Vaccines Inc, a Delaware C-corporation, formally announces today that it has completed the process of acquiring all shares in GPN Vaccines Ltd, a public, unlisted Australian company, resulting in the re-domiciliation of GPN Vaccines to the United States.
GPN Vaccines Inc will continue the development of an ambitious program of innovative bacterial vaccines, initiated by GPN Vaccines Ltd.
The move reflects the company’s global outlook as it advances its lead asset – Gamma-PN – towards a multicentre Phase 2 clinical trial under IND. Establishing a US base is expected to enhance access to the world’s largest healthcare market, expand engagement with leading investors and industry partners, and position the company to accelerate delivery of innovative therapies through the clinic and to patients worldwide.
The re-domiciliation process was approved unanimously by shareholders in May and by the Federal Court of Australia in June. The company will maintain its existing operations in Australia under a wholly owned subsidiary company, GPN Vaccines Pty Ltd.
GPN Vaccines’ CEO and Chairman Dr Tim Hirst said “Re-domiciling to the United States positions GPN Vaccines to access deeper capital markets and a broader investor base, while supporting clinical and commercial growth and ultimately driving long-term value for our shareholders”.
GPN Vaccines’ Chief Financial Officer, James Selkirk, added “We remain deeply committed to our Australian origins and will continue to invest in our partnerships and operations here, while building a broader international presence to support our next phase of growth.”
Correspondence to GPN Vaccines Inc. should be sent to GPN Vaccines Inc, c/o MSF, 125 Park Avenue, New York, NY 10017.
About GPN Vaccines Inc
GPN Vaccines Inc. is a clinical stage Delaware C-corporation developing vaccines against innovative bacterial vaccines, with its lead vaccine targeting Streptococcus pneumoniae. S. pneumoniae is responsible for causing life-threatening pneumonia, bacteraemia and meningitis, as well as otitis media (middle ear infections) and each year causes 1-2 million deaths worldwide, killing more children than AIDS, malaria and tuberculosis combined. There are now more than 100 different serotypes of S. pneumoniae and the best vaccine currently on the market only protects against 21 of them. GPN Vaccines’ product, called Gamma-PN, is being developed to protect children and adults against all S. pneumoniae strains, regardless of serotype.
